carcinoembryonic antigen
carcinoembryonic antigen
Overview
Carcinoembryonic antigen (CEA) is a glycoprotein tumor-associated antigen widely used in oncology as a biomarker and experimental target. It is best known for its clinical association with gastrointestinal malignancies, especially colorectal cancer, but it is also studied across other solid tumors, including gastric, lung, breast, head/neck, melanoma, and prostate cancers. In biomedical research, CEA is valued both as a measurable circulating marker and as a cell-surface target for diagnostic and therapeutic strategies.
Biologically, CEA is relevant because its expression can reflect tumor burden, disease progression, or treatment response in some settings. It is also used as a target antigen for immunotherapy platforms, including CD3-based bispecific T-cell engagers, where binding to CEA on tumor cells can help redirect cytotoxic T cells toward antigen-specific killing. In parallel, CEA is a major focus of biosensor development because sensitive detection can support early diagnosis and treatment monitoring.
Focus of Latest Publications
Recent publications on carcinoembryonic antigen (CEA) have focused heavily on improving its detection as a clinically important cancer biomarker. Several studies developed new biosensing platforms for rapid, sensitive, and portable CEA measurement, including a strain-induced PtCu nanozyme paper-based colorimetric immunoassay with smartphone readout, a coordination/assembly twin-boosted lateral flow immunochromatographic assay using metal-organic framework-mediated signal programming, and a fluorescent “turn-on” aptasensor based on Ce-UiO-66 as an ultraefficient nanoquencher. These approaches used antigen-antibody or aptamer recognition to link CEA concentration to measurable optical signals, and they reported strong analytical performance, including wide detection ranges, low detection limits, and good agreement with clinical serum samples.
Other recent work explored advanced nanomaterial-enabled electrochemical and photoelectrochemical sensing strategies for CEA. A CuInS2 quantum dot aerogel was integrated into a label-free electrochemiluminescence immunosensor, where interparticle charge transport enhanced emission and supported highly sensitive CEA detection. In a separate photoelectrochemical immunoassay, a hollow SnS2/ZnIn2S4@ZnS heterojunction with a tandem built-in electric field was used to amplify photocurrent after CEA-specific sandwich immunorecognition triggered hydrogen sulfide release and subsequent heterojunction formation. Both studies emphasized signal amplification through engineered nanostructures and reported low detection limits with broad linear ranges.
CEA was also investigated in more specialized sensing modalities. One study designed single- and dual-band EIT-like meta-biosensors with T-shaped resonators for specific detection of CEA in the terahertz band, using gold nanoparticles conjugated with CEA antibodies to achieve selective frequency shifts in mixed tumor-marker samples. The authors further applied machine-learning-based spectral classification to distinguish different CEA concentrations. Together, these publications highlight a trend toward label-free, highly sensitive, and data-assisted CEA detection platforms.
Beyond diagnostics, CEA was used as a therapeutic target in colorectal cancer immunotherapy research. A bispecific T-cell engager targeting CEA was combined with L19-TNF, a fusion protein directed to extradomain B of fibronectin, to remodel the tumor microenvironment and enhance cytotoxic T cell activity. The combination increased tumor cell killing and CD8+ T-cell proliferation in vitro, and in vivo it induced complete tumor regression in most animals, prolonged survival, and provided protection against rechallenge. These findings support the use of CEA-directed immunotherapy in combination strategies aimed at converting cold tumors into inflamed, responsive lesions.